Equities

Anteris Technologies Ltd

Anteris Technologies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)9.78
  • Today's Change0.78 / 8.67%
  • Shares traded35.81k
  • 1 Year change-51.10%
  • Beta0.5526
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

  • Revenue in AUD (TTM)7.14m
  • Net income in AUD-87.90m
  • Incorporated1999
  • Employees1.00
  • Location
    Anteris Technologies LtdTOOWONG TOWERSUITE 302, LEVEL 3, 9 SHERWOOD RDTOOWONG 4066AustraliaAUS
  • Phone+61 30055-0310
  • Fax+61 30088-0398
  • Websitehttps://anteristech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImpediMed Ltd10.32m-19.79m107.25m83.00--2.63--10.39-0.0098-0.00980.00510.02010.17831.674.28124,325.30-34.20-44.56-37.62-51.7887.2783.08-191.78-220.516.16--0.0273---9.0419.953.56--6.90--
Respiri Ltd1.04m-7.13m117.48m2.00--39.57--113.12-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m127.78m300.0012.261.368.751.150.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
EchoIQ Ltd44.50k-5.41m132.42m----17.87--2,975.67-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Optiscan Imaging Ltd1.16m-6.06m142.01m8.00--10.24--122.89-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
Orthocell Ltd6.76m-7.18m149.45m----28.86--22.09-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m150.59m87.00--3.17--5.19-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m156.54m----2.43--10.97-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Medadvisor Ltd122.11m792.13k165.39m100.00197.373.2033.161.350.00150.00150.22280.09371.25--11.12--0.8137-15.721.37-24.6060.8159.350.6487-15.38--1.520.1964--24.6467.75107.01--77.57--
EMvision Medical Devices Ltd11.56m-2.73m165.47m----8.93--14.31-0.033-0.0330.14370.21680.6515-------15.38-47.89-20.97-59.47-----23.61-100.24---16.560.1354--62.9959.0629.48------
Anteris Technologies Ltd7.14m-87.90m190.26m1.00--30.46--26.65-5.04-5.040.41220.29550.23613.235.01---304.00-120.86-529.47-189.2768.4366.40-1,287.57-316.850.9233-132.480.3869--4.48-22.85-51.86--42.27--
4DMedical Ltd3.75m-35.98m199.11m----2.81--53.04-0.0972-0.09720.01010.17280.03530.28570.5844---33.79-39.81-41.36-50.9093.6967.64-958.34-1,941.161.74--0.0673--422.4640.12-14.36---1.77--
Aroa Biosurgery Ltd62.61m-9.63m217.29m261.00--2.52--3.47-0.028-0.0280.18210.250.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Imricor Medical Systems Inc1.28m-31.41m218.84m--------171.29-0.1842-0.18420.0073-0.04920.10410.85013.78---255.91-93.47-387.91-106.30-110.81-134.71-2,458.30-2,462.890.799-4.554.73---24.56-9.29-30.36---10.82--
Data as of Nov 18 2024. Currency figures normalised to Anteris Technologies Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

37.52%Per cent of shares held by top holders
HolderShares% Held
L1 Capital Pty Ltd.as of 30 Oct 20243.93m18.59%
Perceptive Advisors LLCas of 10 Apr 20242.14m10.12%
Sio Capital Management LLCas of 10 Apr 20241.03m4.88%
Rhenman & Partners Asset Management ABas of 30 Jun 2024418.70k1.98%
Mutual Trust Pty Ltd.as of 10 Apr 2024271.41k1.28%
Fidelity Management & Research (Hong Kong) Ltd.as of 30 Sep 202476.51k0.36%
Pengana Capital Ltd.as of 28 Jun 202456.52k0.27%
Fideuram Asset Management (Ireland) DACas of 31 Oct 20246.63k0.03%
More ▼
Data from 28 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.